Evidence map›Paper›PMID 40616382›Full record

ReviewBritish journal of haematology2025

Precision transplant and cell therapies for non-malignant disorders-The path forward.

Madhavi Lakkaraja, K Scott Baker

Abstract readReview
In one paragraph

Review in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Madhavi LakkarajaClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-8410-8662
K Scott BakerClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
American Society of HematologyNCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

The number of patients undergoing haematopoietic stem cell transplant (HCT) and cell therapies for non-malignant disorders is steadily increasing with more genetic diseases being identified and newer gene therapy products being introduced for various indications. By combining individualized conditioning, novel graft manipulation techniques, using cutting edge methods to monitor post HCT response and offering exceptional survivorship care, one can achieve excellent survival and improved quality of life for these patients.

Indexed as

Cell- and Tissue-Based TherapyHematopoietic Stem Cell TransplantationPrecision MedicineTransplantation ConditioningGenetic TherapyHumanscell therapynon‐malignant disordersprecisionstem cell transplantation

Identifiers

PMID40616382
PMCPMC12258971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.